首页> 外国专利> Method of Treating Anemia Caused By Ribavirin Treatment of Hepatitis C Using Erythropoietin Alpha

Method of Treating Anemia Caused By Ribavirin Treatment of Hepatitis C Using Erythropoietin Alpha

机译:促红细胞生成素α治疗利巴韦林治疗丙型肝炎引起的贫血的方法

摘要

Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It has not been used for anemia caused by ribavirin. Ribavirin is part of a two-drug regimen now used to treat hepatitis C along with alpha interferon. The principal side effect of ribavirin is a hemolytic anemia. In the past, management of that anemia was done by dose reduction of the ribavirin, sometimes resulting in reversal of part of the anemia. It has become particularly important in light of new data, to maximize the dose of ribavirin given to persons undergoing treatment for hepatitis C to ensure a successful eradication of hepatitis C.
机译:要求并公开的是先前批准的药物的新用途:促红细胞生成素。本发明教导了使用促红细胞生成素来治疗由利巴韦林和α-干扰素的联合治疗引起的贫血。促红细胞生成素先前已被批准用于治疗由癌症化学疗法,肾衰竭和HIV引起的贫血。它尚未用于由利巴韦林引起的贫血。利巴韦林是现在与α干扰素一起用于治疗丙型肝炎的两种药物疗法的一部分。利巴韦林的主要副作用是溶血性贫血。过去,通过减少利巴韦林的剂量来控制该贫血,有时会导致部分贫血的逆转。鉴于新数据,变得尤为重要的是,最大化给予丙型肝炎治疗者的病毒唑剂量,以确保成功消灭丙型肝炎。

著录项

  • 公开/公告号US2013344032A1

    专利类型

  • 公开/公告日2013-12-26

    原文格式PDF

  • 申请/专利权人 DOUGLAS T. DIETERICH;

    申请/专利号US201213728315

  • 发明设计人 DOUGLAS T. DIETERICH;

    申请日2012-12-27

  • 分类号A61K38/18;A61K38/21;A61K31/7056;

  • 国家 US

  • 入库时间 2022-08-21 16:04:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号